Materias dentro de su búsqueda.
Mostrando 1,045,241 - 1,045,260 Resultados de 1,045,414 Para Buscar '"The Times"', tiempo de consulta: 4.79s Limitar resultados
  1. 1045241
    “…As a point of discussion, prolonged rheumatology follow up in KFD may be useful as pathology may persist for some time after the initial clinical presentation. KEY LEARNING POINTS/CONCLUSION: Kikuchi-Fujimoto disease is a rare but recognised cause of pyrexia and lymphadenopathy; it should be considered as a differential in the appropriate clinical scenario. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    P13 A case of Kikuchi-Fujimoto disease triggered by an episode of bacterial cellulitis, associated with features of SLE
  2. 1045242
    “…We hoped this would prove to a positive experience for our patients in a time of great uncertainty. DESCRIPTION/METHOD: Data was collected from patients who attended a weekday virtual PEW (a 3-hour multidisciplinary biopsychosocial intervention) at Evelina London Children’s Hospital between November 2020 and May 2022. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    P09 Does a virtual pain education workshop increase young person understanding of chronic pain, and confidence to self-manage?
  3. 1045243
    por Bray, Lisa, Jeffries, Megan
    Publicado 2022
    “…He was referred to Great Ormond Street Hospital for specialist review by the Ophthalmology team and was noted to have good improvement at that time which has continued on local reviews. There is not complete resolution, and he has a cataract which may need surgical intervention. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    P45 Lyme-associated uveitis: Panuveitis and positive Lyme results – is it a masquerade or the real deal?
  4. 1045244
    “…However, emergency laparotomy should be considered in patients who exhibit signs of peritonism or bowel ischaemia and therefore timely involvement of surgeons and multidisciplinary team is essential.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    OA20 Pneumatosis intestinalis with spontaneous pneumoperitoneum in a patient with systemic sclerosis-myositis overlap syndrome: a case report and review of the literature
  5. 1045245
    por Marie, Ditte, Saunte, Lindhardt
    Publicado 2022
    “…They differ in several ways including inoculum concentration, incubation temperature, incubation time, different culture media, and end-point criterion of fungal growth (percentage of growth inhibition)(9,10). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    S6.2b In vitro susceptibility testing of dermatophytes: toward standardization
  6. 1045246
    “…Given the increasing penetration of these tools and growing media literacy on one end, with widening gender‐based gaps on the other, it is imperative to gather more high‐quality evidence on their effectiveness. Timely evidence generation can help leverage these platforms appropriately and enable intervention designs that are responsive to changing communication ecologies of AGYW. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evidence and gap map report: Social and Behavior Change Communication (SBCC) interventions for strengthening HIV prevention and research among adolescent girls and young women (AGYW) in low‐ and middle‐income countries (LMICs)
  7. 1045247
    “…Other factors, including concomitant prednisolone use, rituximab-associated factors (eg, rituximab dose and time to vaccination since last rituximab dose), and vaccine-associated factors (eg, vaccine type and peripheral B-cell depletion) were not predictive of moderate-to-severe COVID-19 outcomes. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study
  8. 1045248
    “…Milch Employee of: former employee, was employed at Eli Lilly and Company at the time of study, M. Abreu Grant / Research support from: Pfizer, Prometheus Biosciences, and Takeda, Consultant of: AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Eli Lilly and Company, Gilead Sciences, Janssen, Microba Life Sciences, Prometheus Biosciences, UCB Pharma, and WebMD, Speakers bureau of: Alimentiv, Intellisphere LLC (HCP Live Institutional Perspectives in GI), Janssen, Prime CME, and Takeda, J. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A184 EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL
  9. 1045249
    por Langsteger, W, Rezaee, A, Loidl, W, Geinitz, HS, Fitz, F, Steinmair, M, Broinger, G, Pallwien-Prettner, L, Beheshti, M, Imamovic, L, Beheshti, M, Rendl, G, Hackl, D, Tsybrovsky, O, Steinmair, M, Emmanuel, K, Moinfar, F, Pirich, C, Langsteger, W, Bytyqi, A, Karanikas, G, Mayerhöfer, M, Koperek, O, Niederle, B, Hartenbach, M, Beyer, T, Herrmann, K, Czernin, J, Rausch, I, Rust, P, DiFranco, MD, Lassen, M, Stadlbauer, A, Mayerhöfer, ME, Hartenbach, M, Hacker, M, Beyer, T, Binzel, K, Magnussen, R, Wei, W, Knopp, MU, Flanigan, DC, Kaeding, C, Knopp, MV, Leisser, A, Nejabat, M, Hartenbach, M, Kramer, G, Krainer, M, Hacker, M, Haug, A, Lehnert, Wencke, Schmidt, Karl, Kimiaei, Sharok, Bronzel, Marcus, Kluge, Andreas, Wright, CL, Binzel, K, Zhang, J, Wuthrick, Evan, Maniawski, Piotr, Knopp, MV, Blaickner, M, Rados, E, Huber, A, Dulovits, M, Kulkarni, H, Wiessalla, S, Schuchardt, C, Baum, RP, Knäusl, B, Georg, D, Bauer, M, Wulkersdorfer, B, Wadsak, W, Philippe, C, Haslacher, H, Zeitlinger, M, Langer, O, Bauer, M, Feldmann, M, Karch, R, Wadsak, W, Zeitlinger, M, Koepp, MJ, Asselin, M-C, Pataraia, E, Langer, O, Zeilinger, M, Philippe, C, Dumanic, M, Pichler, F, Pilz, J, Hacker, M, Wadsak, W, Mitterhauser, M, Nics, L, Steiner, B, Hacker, M, Mitterhauser, M, Wadsak, W, Traxl, A, Wanek, Thomas, Kryeziu, Kushtrim, Mairinger, Severin, Stanek, Johann, Berger, Walter, Kuntner, Claudia, Langer, Oliver, Mairinger, S, Wanek, T, Traxl, A, Krohn, M, Stanek, J, Filip, T, Sauberer, M, Kuntner, C, Pahnke, J, Langer, O, Svatunek, D, Denk, C, Wilkovitsch, M, Wanek, T, Filip, T, Kuntner-Hannes, C, Fröhlich, J, Mikula, H, Denk, C, Svatunek, D, Wanek, T, Mairinger, S, Stanek, J, Filip, T, Fröhlich, J, Mikula, H, Kuntner-Hannes, C, Balber, T, Singer, J, Fazekas, J, Rami-Mark, C, Berroterán-Infante, N, Jensen-Jarolim, E, Wadsak, W, Hacker, M, Viernstein, H, Mitterhauser, M, Denk, C, Svatunek, D, Sohr, B, Mikula, H, Fröhlich, J, Wanek, T, Kuntner-Hannes, C, Filip, T, Pfaff, S, Philippe, C, Mitterhauser, M, Hartenbach, M, Hacker, M, Wadsak, W, Wanek, T, Halilbasic, E, Visentin, M, Mairinger, S, Stieger, B, Kuntner, C, Trauner, M, Langer, O, Lam, P, Aistleitner, M, Eichinger, R, Artner, C, Eidherr, H, Vraka, C, Haug, A, Mitterhauser, M, Nics, L, Hartenbach, M, Hacker, M, Wadsak, W, Kvaternik, H, Müller, R, Hausberger, D, Zink, C, Aigner, RM, Cossío, U, Asensio, M, Montes, A, Akhtar, S, te Welscher, Y, van Nostrum, R, Gómez-Vallejo, V, Llop, J, VandeVyver, F, Barclay, T, Lippens, N, Troch, M, Hehenwarter, L, Egger, B, Holzmannhofer, J, Rodrigues-Radischat, M, Pirich, C, Pötsch, N, Rausch, I, Wilhelm, D, Weber, M, Furtner, J, Karanikas, G, Wöhrer, A, Mitterhauser, M, Hacker, M, Traub-Weidinger, T, Cassou-Mounat, T, Balogova, S, Nataf, V, Calzada, M, Huchet, V, Kerrou, K, Devaux, J-Y, Mohty, M, Garderet, L, Talbot, J-N, Stanzel, S, Pregartner, G, Schwarz, T, Bjelic-Radisic, V, Liegl-Atzwanger, B, Aigner, R, Stanzel, S, Quehenberger, F, Aigner, RM, Marković, A Koljević, Janković, Milica, Jerković, V Miler, Paskaš, M, Pupić, G, Džodić, R, Popović, D, Fornito, MC, Familiari, D, Koranda, P, Polzerová, H, Metelková, I, Henzlová, L, Formánek, R, Buriánková, E, Kamínek, M, Thomson, WH, Lewis, C, Thomson, WH, O’Brien, J, James, G, Notghi, A, Huber, H, Stelzmüller, I, Wunn, R, Mandl, M, Fellner, F, Lamprecht, B, Gabriel, M, Fornito, MC, Leonardi, G, Thomson, WH, O’Brien, J, James, G, Hudzietzová, J, Sabol, J, Fülöp, M
    Publicado 2016
    “…L Imamovic, M Beheshti, G Rendl, D Hackl, O Tsybrovsky, M Steinmair, K Emmanuel, F Moinfar, C Pirich, W Langsteger A3 [18F]Fluoro-DOPA-PET/CT in the primary diagnosis of medullary thyroid carcinoma A Bytyqi, G Karanikas, M Mayerhöfer, O Koperek, B Niederle, M Hartenbach A4 Variations of clinical PET/MR operations: An international survey on the clinical utilization of PET/MRI T Beyer, K Herrmann, J Czernin A5 Standard Dixon-based attenuation correction in combined PET/MRI: Reproducibility and the possibility of Lean body mass estimation I Rausch, P Rust, MD DiFranco, M Lassen, A Stadlbauer, ME Mayerhöfer, M Hartenbach, M Hacker, T Beyer A6 High resolution digital FDG PET/MRI imaging for assessment of ACL graft viability K Binzel, R Magnussen, W Wei, MU Knopp, DC Flanigan, C Kaeding, MV Knopp A7 Using pre-existing hematotoxicity as predictor for severe side effects and number of treatment cycles of Xofigo therapy A Leisser, M Nejabat, M Hartenbach, G Kramer, M Krainer, M Hacker, A Haug A8 QDOSE – comprehensive software solution for internal dose assessment Wencke Lehnert, Karl Schmidt, Sharok Kimiaei, Marcus Bronzel, Andreas Kluge A9 Clinical impact of Time-of-Flight on next-generation digital PET imaging of Yttrium-90 radioactivity following liver radioembolization CL Wright, K Binzel, J Zhang, Evan Wuthrick, Piotr Maniawski, MV Knopp A10 Snakes in patients! …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    32nd International Austrian Winter Symposium: Zell am See, the Netherlands. 20-23 January 2016
  10. 1045250
    “…HFIM, ETP and TBP free-drug concentration-time profiles were simulated in the HFIM to represent those following IV and PO dosing, respectively. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1113. Oral Tebipenem as Step-Down Therapy Following Intravenous Ertapenem in a 7-day Hollow-Fiber In Vitro Infection Model
  11. 1045251
    Enlace del recurso
    Enlace del recurso
    CPsuperH2.3: an Updated Tool for Phenomenology in the MSSM with Explicit CP Violation
  12. 1045252
    “…Additionally, paired EVs and ECs were isolated from EDTA blood plasma of combination anti-retroviral therapy (cART) naïve SIV-infected (SIV+, n = 3) RMs at two time points (1- and 5-months post infection, 1 MPI and 5 MPI). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    SIV Infection Regulates Compartmentalization of Circulating Blood Plasma miRNAs within Extracellular Vesicles (EVs) and Extracellular Condensates (ECs) and Decreases EV-Associated miRNA-128
  13. 1045253
    “…Any type of formal or informal educational intervention, lasting for any time, that had content focused directly on knowledge about IBD or skills needed for direct management of IBD or its symptoms was included. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Patient education interventions for the management of inflammatory bowel disease
  14. 1045254
    “…For studies included in the meta‐analyses, Housing First had the largest observed impact, followed by Assertive Community Treatment, Critical Time Intervention and Intensive Case Management. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Exploring the effect of case management in homelessness per components: A systematic review of effectiveness and implementation, with meta‐analysis and thematic synthesis
  15. 1045255
    “…BACKGROUND: Pelvic, hip, and long bone fractures can result in significant bleeding at the time of injury, with further blood loss if they are treated with surgical fixation. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint replacement for hip, pelvic and long bone fractures
  16. 1045256
    “…Serum biomarker changes from the pre-operative to the 6-month post-ACLR time points had no predictive value with respect to patient reporting of clinically relevant knee OA symptoms 12 months post-ACLR. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Paper 09: Serum Biochemical Biomarker Profiles Linked to Poor Knee Joint Health Are Not Associated with OA-Related Symptoms at 12 Months Post-ACLR
  17. 1045257
    “…SELECTION CRITERIA: We included randomised controlled trials (RCTs) (randomisation at individual or cluster level), non‐randomised controlled trials, interrupted time series with at least three measure points both before and after intervention, and controlled before‐after studies. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Fortification of condiments and seasonings with iron for preventing anaemia and improving health
  18. 1045258
    “…DISCLAIMER: This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evidence-based guideline: unexplained infertility
  19. 1045259
    “…RESULTS: Of children 6 mo to < 5 y old (6 mo to < 2 y, n = 24; 2 y to < 5 y, n = 36) who received bivalent BNT162b2 as a fourth dose, 50% were male, 58% White, 5% Black, 15% Asian, 22% multiracial, 25% Hispanic/Latino; 28.3% had evidence of past SARS-CoV-2 infection. Median time from dose 3 of original BNT162b2 to bivalent BNT162b2 was 6.5 mo. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    362. Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to Toddlers and Children 6 Months to < 5 Years of Age Who Previously Received Original BNT162b2 as a 3-Dose Primary Series
  20. 1045260
    “…Ppts with preexisting PRMs were older (≥ 50 years), had more prior ARTs and more prior virologic failure, and had a longer time between HIV diagnosis and starting B/F/TAF versus those without PRMs. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1611. Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Experienced People With HIV and a History of Antiretroviral Drug Resistance Mutations
Herramientas de búsqueda: RSS